Lost your password?
Don't have an account? Sign Up

Madrigal Pharmaceuticals Stock Jumps 260%

Madrigal Pharmaceuticals shares jumped over 200% in morning trading!

Market reacted after the company said it say “positive topline results” from a late-stage clinical trial of resmetirom, a treatment for liver conditions.

Tweet on Madrigal Pharma.stock

Company official announcement

Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases.

Company’s most advanced clinical candidate, is resmetirom, that has the potential to become the first medication approved for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis according to Madrigal.co

Tweet on the current stock fluctuation

Factset chart on stock

Madrigal stock was recently up some 260% to about $229. It closed Friday below $64.

The company intends to file a new drug application in the first half of 2023 seeking accelerated approval for resmetirom.